Resources

Product Brochure
Request More Information
USA / Product Areas / Vascular Access / Peripheral Access / Midline Catheters / Arrowg+ard Blue Advance™ Midline

Arrowg+ard Blue Advance™ Midline

Designed to address typical complaints of today’s midlines, the pressure-injectable Arrowg+ard Blue Advance™ Midline is the only midline with antithrombogenic and antimicrobial properties.1,2 Using a familiar insertion technique, it offers critical innovations appreciated by vascular access specialists, patients, and hospitals.

  • The Arrowg+ard Blue Advance™ Midline reduces the risk of catheter-related complications—including occlusion, phlebitis, and fibrin sheath accumulation on catheter surfaces—for at least 29 days1,3
  • Designed to actually inhibit fibrin sheath formation on the catheter surface1
  • GlideThru® Sheath and Blue FlexTip® Feature to minimize vessel damage4
View Our Product Catalog

 

Arrowg+ard Blue Advance™ Midline Maximal Barrier Precautions • Modified Seldinger Technique • Bedside Insertion Trays

Available in an ergonomically optimized Arrow® ErgoPack® System, with all components needed and arranged in order of use for maximal barriers precautions and clinician safety.

Product

Description

NO Latex*

CDC-41541-MPK1A

4.5 Fr. x 15 cm Pressure Injectable Arrow® Midline with Maximal Barrier Precautions Modified Seldinger Insertion Tray

✔

CDC-41552-MPK1A

5.5 Fr. x 15 cm Pressure Injectable Arrow® Midline with Maximal Barrier Precautions Modified Seldinger Insertion Tray

✔

*Kit contents are not made with natural rubber latex.

For custom procedural kits that fit your facility’s specific preferences, contact your Teleflex sales representative or call 800.523.8446.

References:

  1. Ryder MA, et al. The Effect of Chlorhexidine Catheter Coating Compared to an Uncoated and Biomimetic Catheter on the Reduction of Fibrin Sheath Formation in an in vivo Clinically Simulated Ovine Model. Infusion Nurses Society Annual Convention and Industrial Exhibition; 2012. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.
  2. Ryder MA, et al. The Effect of Chlorhexidine Catheter Coating Compared to a Biomimetic Catheter on the Reduction of Fibrin Sheath Formation in the presence of Staphylococcus aureus colonization in an in vivo Clinically Simulated Ovine Model. Nurses Society Annual Convention and Industrial Exhibition; 2012. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.
  3. As compared to uncoated PICCs, in vitro model measuring flush pressure post exposure to human blood. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.
  4. Rosenbauer KA, Herzer JA. Surface morphology and tensile force at breaking point or different kinds of intravenous catheters before and after usage. Scan Electron Microsc. 1981;(Pt 3):125-30.
  5. Collins JL, Lutz RJ. In vitro study of simultaneous infusion of incompatible drugs in multilumen catheters. Heart & Lung. 1991; 20(3):271-7.

Rx only

Contraindication:

The Arrowg+ard Blue Advance™ Midline is contraindicated for patients with known hypersensitivity to chlorhexidine.

No correlation between in vitro / in vivo testing methods and clinical outcomes have currently been ascertained.

* Indwell time is up to 30 days.

Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue Advance, Blue FlexTip, ErgoPack and GlideThru are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are trademarks of their respective owners. MC-002741 Rev 0.1

OUR PRODUCTS

TELEFLEX MEDICAL OEM

SUPPLIERS

ABOUT US

CAREERS

INVESTORS

LEGAL

GLOBAL REACH

SERVICES

CONTACT

© Teleflex Incorporated. All Rights Reserved.